Latigo Biotherapeutics LTGO

Nima Farzan has served as our Chief Executive Officer and a member of our board of directors since July 2024. Previously, Mr. Farzan served as an Executive-in-Residence at Foresite Capital, a life sciences focused venture capital firm, from April 2024 to July 2024. From March 2020 to April 2024, Mr. Farzan served as Chief Executive Officer and a member of the board of directors of Kinnate Biopharma, Inc., a publicly held biotechnology company, where he advanced three precision oncology compounds into clinical development and led the company through its initial public offering and subsequent acquisition by XOMA Corporation. From October 2018 to February 2020, Mr. Farzan served as an advisor for several life sciences companies, including Emergent BioSolutions, Inc. and MODA Pharmaceuticals. From September 2011 to October 2018, Mr. Farzan served in several capacities, including as President, Chief Executive Officer and member of the board of directors of PaxVax, Inc., a privately held specialty vaccine company (acquired by Emergent BioSolutions). Prior to PaxVax, Mr. Farzan held various positions of increasing seniority, including Vice President of U.S. Marketing, at Novartis AG, a publicly held pharmaceutical company, and served as an associate at The Boston Consulting Group, a privately held business consulting firm. Mr. Farzan has served on the board of directors of Keros Therapeutics, Inc., a publicly held biopharmaceutical company, since March 2020. Mr. Farzan earned his B.A. in Human Biology with honors from Stanford University and his M.B.A. from Harvard Business School.

Neil Singla, M.D. has served as our Chief Medical Officer since April 2024. Dr. Singla founded Lotus Clinical Research, LLC (Lotus), a specialty clinical research company, and served in several positions from March 2001 to March 2024, including as Chief Executive Officer and Chief Scientific Officer. During his tenure at Lotus, Dr. Singla expanded the company into a network of specialty research centers, a full-service clinical research organization and a scientific and regulatory consulting firm. From May 2012 to November 2019, Dr. Singla also served as Chairman of the Clinical Trials Special Interest Group for the International Association for the Study of Pain (IASP) and the Clinical Trials Shared Interest Group of the American Pain Society (APS), organizing and chairing scientific symposia on analgesic trials. Dr. Singla earned his B.S. in Biology from the University of Akron and his M.D. at Northeast Ohio Medical University. He completed his residency in Anesthesiology at Loma Linda University Medical Center, where he served as Chief Resident and Teaching Scholar of the Year.

Neha Krishnamohan has served as our Chief Financial Officer and Chief Business Officer since February 2026. Prior to becoming our Chief Financial Officer and Chief Business Officer, Ms. Krishnamohan served as a member of our board of directors and Chair of our Audit Committee from April 2025 to February 2026. Ms. Krishnamohan served as Chief Financial Officer and Executive Vice President of Corporate Development at Artiva Biotherapeutics, Inc., a publicly held biotechnology company, from April 2024 to December 2025. Previously, from June 2021 to April 2024, Ms. Krishnamohan served as Chief Financial Officer and Executive Vice President of Corporate Development at Kinnate Biopharma Inc., a publicly held biotechnology company, until its acquisition by XOMA Corporation. From July 2008 to June 2021, Ms. Krishnamohan worked at Goldman Sachs & Co. LLC, an investment bank, where she served most recently as Vice President, Healthcare Investment Banking, from January 2015 to June 2021, and as an Associate in the Healthcare Investment Banking Group, from August 2011 to December 2014. Ms. Krishnamohan has served on the board of directors of Arcutis Biotherapeutics, Inc., a publicly held biopharmaceutical company, since September 2022. Ms. Krishnamohan earned her B.S.E. with a double major in Biomedical Engineering and Economics from Duke University.

Timothy P. Walbert has served as Chairman of our board of directors since October 2024. Since October 2023, Mr. Walbert has served as a senior advisor to Amgen Inc., a publicly held biotechnology company. Previously, Mr. Walbert was Chairman, President and Chief Executive Officer of Horizon Therapeutics Public Ltd Co (Horizon), a biotechnology company (acquired by Amgen), from June 2008 to October 2023. Prior to Horizon, he served as President, Chief Executive Officer and a member of the board of directors of IDM Pharma Inc., a biotechnology company (acquired by Takeda Pharmaceuticals). Prior to that, Mr. Walbert served as Executive Vice President, Commercial Operations at NeoPharm Inc., a publicly held biotechnology company. Mr. Walbert has served on the board of directors of multiple publicly held biotechnology companies, including Century Therapeutics, Inc. since September 2022, Mirum Pharmaceuticals, Inc. since April 2023, Sagimet Biosciences Inc. since March 2024, and BioMarin Pharmaceutical Inc. since February 2025, as well as Cour Pharmaceuticals Development Co., Inc. since June 2024, Odyssey Therapeutics, Inc. since October 2024, and Catalent, Inc. since February 2025 and Crystalys Therapeutics, Inc. since February 2026. He previously served on the board of directors of Aurinia Pharmaceuticals Inc., a publicly held pharmaceutical company, from 2020 to 2022, Exicure, Inc., a publicly held biotechnology company, from 2019 to 2022, Assertio Holdings, Inc., a publicly held biopharma company, from 2014 to 2020, Raptor Pharmaceutical Corp., a publicly held biotechnology company, from 2010 to 2014, XOMA Corporation, a publicly held biotechnology company, from 2011 to 2017, and Sucampo Pharmaceuticals Inc., a publicly held biopharmaceutical company, from 2016 to 2018. Mr. Walbert was previously a member of the board of directors of the Biotechnology Innovation Organization, the Pharmaceutical Research and Manufacturing Association, the Illinois Biotechnology Innovation Organization and World Business Chicago. Mr. Walbert earned his B.A. in Business from Muhlenberg College.

Kevin Raidy has served as a member of our board of directors since January 2025. Since December 2023, Mr. Raidy has served as Senior Managing Director and Head of Healthcare Opportunities at Blue Owl Capital, an asset management company, overseeing all private and public equity investment activities related to healthcare opportunities. From November 2017 to December 2023, Mr. Raidy founded and served as Managing Partner of Cowen Healthcare Investments (Cowen), which later became part of Blue Owl Capital. At Cowen, Mr. Raidy served as Head of Investment Banking from January 2012 to November 2017 and as Co-Head of the Equity Capital Markets Group from June 2010 to January 2012. From August 1993 to January 2003, Mr. Raidy worked at Shipley Raidy Capital Partners, a boutique investment banking firm he co-founded. Mr. Raidy serves as a member of the board of directors at NodThera Ltd., Neuron23, Sundance Biosciences and Aro Biopharmaceuticals, each a privately held biotechnology company. Mr. Raidy earned his B.S. in Economics with a concentration in Finance from the Wharton School of the University of Pennsylvania.

Todd N. Smith has served as a member of our board of directors since May 2026. Mr. Smith has served as Chief Executive Officer at Corium, LLC, a privately held biopharmaceutical company, since July 2024, as Operating Partner of NewVale Capital, LLC, a life sciences-focused growth equity firm, since January 2024, as Senior Advisor at Athyrium Capital Management, LP, a life sciences-focused investment firm, since September 2024, and as Founder of Apollo Care, LLC, a privately held healthcare technology company (Apollo Care), since January 2021. He previously served as Chief Executive Officer at Valinor Pharma, LLC, a privately held pharmaceutical company (Valinor Pharma) (acquired by Grunenthal), from April 2023 to July 2024, as President, Chief Commercial Officer and Head of Business Development at Tolmar Pharmaceuticals, Inc., a privately held pharmaceutical company (Tolmar Pharmaceuticals), from March 2022 to April 2023, and as Chief Executive Officer of Assertio Holdings, Inc., a publicly held pharmaceutical company (Assertio Holdings), from January 2017 to December 2020. Mr. Smith has served as a member of the board of directors of Quetzal Therapeutics, LLC, a privately held biopharmaceutical company, since October 2025, as a member of the board of directors of BVI Medical, Inc., a privately held medical device company, since July 2017, and as a member of the board of directors of Apollo Care since January 2021. Previously, Mr. Smith served as a member of the board of directors of Vault Pharma, Inc., a privately held biotechnology company, from June 2015 to September 2025, as a member of the board of directors of Valinor Pharma from April 2023 to July 2024, as a member of the board of directors of Bright Path Laboratories, Inc., a privately held biotechnology company, from September 2016 to March 2023, as a member of the board of directors of Tolmar Pharmaceuticals from March 2022 to April 2023, and as a member of the board of directors of Assertio Holdings from January 2017 to December 2020. Mr. Smith holds a B.A. in political science from Norwich University.

Sara M. Bonstein has served as a member of our board of directors since April 2026. Ms. Bonstein has more than two decades of operational and financial leadership in the life sciences industry and has served as Chief Financial Officer at Insmed, Inc., a biopharmaceutical company, since January 2020. Prior to joining Insmed, she served as Chief Financial Officer and Chief Operating Officer at OncoSec Medical Incorporated, a biotechnology company, from May 2018 to January 2020 and as Chief Financial Officer at Advaxis, Inc., a biotechnology company, from February 2014 to April 2018. Prior to Advaxis, Ms. Bonstein served in various finance roles of increasing responsibility, including at Eli Lilly & Company and Johnson & Johnson. Ms. Bonstein has served as a member of the board of directors of Xilio Therapeutics, Inc., a public biotechnology company, since August 2021. Previously, Ms. Bonstein served on the board of directors of scPharmaceuticals Inc., a public pharmaceutical company (acquired by MannKind Corporation), from August 2021 to August 2025. Ms. Bonstein holds a B.S. in finance from The College of New Jersey and an M.B.A. from Rider University.

James Tananbaum, M.D. has served as a member of our board of directors since July 2024. Since June 2010, Dr. Tananbaum has served as the President, Chief Executive Officer and a director of Foresite Capital Management LLC, a U.S.-focused healthcare investment firm, which he founded. From 2000 to 2010, Dr. Tananbaum served as Co-Founder and Managing Director of Prospect Venture Partners L.P. II and III, healthcare venture partnerships. Previously, Dr. Tananbaum founded Theravance, Inc. (now Theravance Biopharma, Inc., a publicly held biopharmaceutical company, and Innoviva, Inc., a publicly held healthcare asset management company) in 1997. Prior to that, Dr. Tananbaum founded GelTex, Inc., a pharmaceutical company (acquired by Sanofi-Genzyme) in 1991. Dr. Tananbaum has served on the board of directors of Alumis, Inc., a publicly held biopharmaceutical company, since January 2021, and Eikon Therapeutics, Inc., a publicly held biopharmaceutical company, since September 2019. Dr. Tananbaum previously served on the board of directors of Fabric Genomics, a privately held biotechnology company, from December 2019 to April 2025, Kinnate Biopharma, Inc., a publicly held biotechnology company, from June 2020 to April 2024, and Quantum-SI Incorporated, a publicly held biotechnology company, from June 2021 to May 2022. Dr. Tananbaum earned his B.S. and B.S.E.E. in Applied Math and Electrical Engineering/Computer Science from Yale University and his M.B.A. and M.D. from Harvard University.

Beth Seidenberg, M.D. has served as a member of our board of directors since July 2024. Dr. Seidenberg has served as a founding Managing Director of Westlake BioPartners, a life sciences venture capital firm, since September 2018. Since May 2005, Dr. Seidenberg has served as Managing Member of venture capital funds advised by Kleiner Perkins Caufield and Byers, LLC, a venture capital firm, where she primarily focuses on life sciences investing. From February 2002 to May 2005, Dr. Seidenberg served as the Senior Vice President, Head of Global Development and Chief Medical Officer at Amgen Inc., a publicly held biotechnology company. Prior to that, Dr. Seidenberg held various positions, including as Senior Vice President of Global Development at Bristol-Myers Squibb Company, a publicly held biopharmaceutical company, and as Vice President of Pulmonary-Immunology at Merck & Co., Inc., a publicly held biopharmaceutical company. Dr. Seidenberg has served on the board of directors of Vera Therapeutics, Inc., a publicly held biotechnology company, since June 2016, Kyverna Therapeutics, Inc., a publicly held biopharmaceutical company, since September 2018, Sagimet Biosciences Inc., a publicly held biotechnology company, since April 2007, and several other privately held life sciences companies. Dr. Seidenberg previously served on the board of directors of Acelyrin, Inc., a publicly held biopharmaceutical company, from October 2020 to March 2025, Atara Biotherapeutics, Inc., a publicly held biopharmaceutical company from August 2012 to June 2023, and Progyny, Inc., a publicly held fertility benefit management company, from May 2010 to November 2024. Dr. Seidenberg earned her B.S. in Biology and Anthropology from Barnard College and her M.D. from the University of Miami School of Medicine and completed her post-graduate training at the Johns Hopkins University, George Washington University and the National Institutes of Health.

Deborah Palestrant, Ph.D. has served as a member of our board of directors since August 2020. Since November 2018, Dr. Palestrant has served as a Partner of 5AM Ventures, a venture capital firm focused on life sciences companies, and Partner and Executive Chair of 4:59 Initiative, a 5AM Ventures company. From July 2017 to November 2018, Dr. Palestrant served as Vice President of Corporate Development & Strategy at Relay Therapeutics, Inc., a publicly held precision medicines company. From November 2013 to July 2017, Dr. Palestrant served as Senior Director of Business Development & Strategy at Editas Medicine, Inc., a publicly held biotechnology company. Dr. Palestrant has served as a member of the board of directors of multiple privately held biopharmaceutical companies, including Renasant Bio since March 2023, Nido Biosciences, Inc. since September 2023, and Falcon Bio since November 2024. She has also served as a member of the board of directors and as Treasurer of the New England Venture Capital Association since January 2020 and as a member of the board of managers of Life Science Cares Boston since December 2023. Dr. Palestrant previously served on the board of directors of multiple privately held biotechnology and biopharmaceutical companies, including Nvelop Therapeutics from July 2022 to December 2024, Seeker Biologics, Inc. from March 2019 to October 2023, and Ziada Therapeutics, Inc. from February 2024 to December 2025. Dr. Palestrant earned her B.S. in Biochemistry at the University of California, Los Angeles, her M.B.A. from Northeastern University and her Ph.D. in Biochemistry and Molecular Biophysics from Columbia University, and completed a postdoctoral fellowship at The Scripps Research Institute.